The global renal anemia therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of chronic kidney disease and other renal diseases, which are major causes for renal anemia. The increase in the number of patients with chronic kidney disease and other renal diseases will lead to a rise in demand for therapeutic products that can treat these conditions. The global renal anemia therapeutics market by type includes D1093, EP018B, F2216, JT951, MDG201 and MM0101.D1093 is used as a treatment for acute or chronic kidney failure due to its ability to inhibit erythropoietin production by binding with erythropoietin receptors on bone marrow cells. EP018B is used as a treatment for acute or chronic kidney failure due to its ability to inhibit erythropoietin production by binding with erythropoietin receptors on bone marrow cells. F2216 is used as a treatment for acute or chronic kidney failure due to its ability to inhibit erythropoietin production by binding with erythropoietin receptors on bone marrow cells. JT951 is used as a treatment for acute or chronic kidney failure due to its ability to inhibit erythropoietin production by binding with erythropoietin receptors on bone marrow cells; it also has anti-inflammatory properties that help reduce inflammation in the kidneys and prevent further damage from occurring in these organs when they are already damaged from high blood pressure or diabetes mellitus type 2 (DM2).
Some Of The Growth Factors Of This Market:
- Increasing prevalence of chronic kidney disease and other renal diseases is driving the growth of the global Renal Anemia Therapeutics market.
- Rising awareness about renal anemia and its treatment options among patients is also driving the growth of this market globally.
- Increasing number of clinical trials for new drugs in this segment are also expected to drive the growth of this market globally during the forecast period, 2018-2025 The increasing number of clinical trials for new drugs in this segment are also expected to drive the growth of this market globally during the forecast period, 2018-2025.
Industry Growth Insights published a new data on “Renal Anemia Therapeutics Market”. The research report is titled “Renal Anemia Therapeutics Market research by Types (DS-1093, EPO-018B, FG-2216, JTZ-951, MDGN-201, MMP-0101, Others), By Applications (Hospital, Research Center, Clinic), By Players/Companies Bayer AG, BIOCAD, CCM Duopharma Biotech Bhd., Chong Kun Dang Pharmaceutical Corp., Daiichi Sankyo Company, Limited, Dong-A Socio Group, Dr. Reddy's Laboratories Limited, Eli Lilly and Company, FibroGen, Inc., GlaxoSmithKline Plc, Intas Pharmaceuticals Ltd., Japan Tobacco Inc., JCR Pharmaceuticals Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd.”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Renal Anemia Therapeutics Market Research Report
By Type
DS-1093, EPO-018B, FG-2216, JTZ-951, MDGN-201, MMP-0101, Others
By Application
Hospital, Research Center, Clinic
By Companies
Bayer AG, BIOCAD, CCM Duopharma Biotech Bhd., Chong Kun Dang Pharmaceutical Corp., Daiichi Sankyo Company, Limited, Dong-A Socio Group, Dr. Reddy's Laboratories Limited, Eli Lilly and Company, FibroGen, Inc., GlaxoSmithKline Plc, Intas Pharmaceuticals Ltd., Japan Tobacco Inc., JCR Pharmaceuticals Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Renal Anemia Therapeutics Market Report Segments:
The global Renal Anemia Therapeutics market is segmented on the basis of:
Types
DS-1093, EPO-018B, FG-2216, JTZ-951, MDGN-201, MMP-0101, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Research Center, Clinic
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer AG
- BIOCAD
- CCM Duopharma Biotech Bhd.
- Chong Kun Dang Pharmaceutical Corp.
- Daiichi Sankyo Company, Limited
- Dong-A Socio Group
- Dr. Reddy's Laboratories Limited
- Eli Lilly and Company
- FibroGen, Inc.
- GlaxoSmithKline Plc
- Intas Pharmaceuticals Ltd.
- Japan Tobacco Inc.
- JCR Pharmaceuticals Co., Ltd.
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Highlights of The Renal Anemia Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- DS-1093
- EPO-018B
- FG-2216
- JTZ-951
- MDGN-201
- MMP-0101
- Others
- By Application:
- Hospital
- Research Center
- Clinic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Renal Anemia Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Renal anemia therapeutics is a field of medicine that focuses on the treatment of renal anemia. This includes the use of medications, supplements, and other treatments to help improve blood flow to the kidneys and increase the amount of oxygen available to them.
Some of the major players in the renal anemia therapeutics market are Bayer AG, BIOCAD, CCM Duopharma Biotech Bhd., Chong Kun Dang Pharmaceutical Corp., Daiichi Sankyo Company, Limited, Dong-A Socio Group, Dr. Reddy's Laboratories Limited, Eli Lilly and Company, FibroGen, Inc., GlaxoSmithKline Plc, Intas Pharmaceuticals Ltd., Japan Tobacco Inc., JCR Pharmaceuticals Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd..
The renal anemia therapeutics market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Renal Anemia Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Renal Anemia Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Renal Anemia Therapeutics Market - Supply Chain
4.5. Global Renal Anemia Therapeutics Market Forecast
4.5.1. Renal Anemia Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Renal Anemia Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Renal Anemia Therapeutics Market Absolute $ Opportunity
5. Global Renal Anemia Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Renal Anemia Therapeutics Market Size and Volume Forecast by Type
5.3.1. DS-1093
5.3.2. EPO-018B
5.3.3. FG-2216
5.3.4. JTZ-951
5.3.5. MDGN-201
5.3.6. MMP-0101
5.3.7. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Renal Anemia Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Renal Anemia Therapeutics Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Research Center
6.3.3. Clinic
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Renal Anemia Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Renal Anemia Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Renal Anemia Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Renal Anemia Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Renal Anemia Therapeutics Demand Share Forecast, 2019-2026
9. North America Renal Anemia Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Renal Anemia Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Renal Anemia Therapeutics Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Research Center
9.4.3. Clinic
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Renal Anemia Therapeutics Market Size and Volume Forecast by Type
9.7.1. DS-1093
9.7.2. EPO-018B
9.7.3. FG-2216
9.7.4. JTZ-951
9.7.5. MDGN-201
9.7.6. MMP-0101
9.7.7. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Renal Anemia Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Renal Anemia Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Renal Anemia Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Renal Anemia Therapeutics Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Research Center
10.4.3. Clinic
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Renal Anemia Therapeutics Market Size and Volume Forecast by Type
10.7.1. DS-1093
10.7.2. EPO-018B
10.7.3. FG-2216
10.7.4. JTZ-951
10.7.5. MDGN-201
10.7.6. MMP-0101
10.7.7. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Renal Anemia Therapeutics Demand Share Forecast, 2019-2026
11. Europe Renal Anemia Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Renal Anemia Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Renal Anemia Therapeutics Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Research Center
11.4.3. Clinic
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Renal Anemia Therapeutics Market Size and Volume Forecast by Type
11.7.1. DS-1093
11.7.2. EPO-018B
11.7.3. FG-2216
11.7.4. JTZ-951
11.7.5. MDGN-201
11.7.6. MMP-0101
11.7.7. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Renal Anemia Therapeutics Demand Share, 2019-2026
12. Asia Pacific Renal Anemia Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Renal Anemia Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Renal Anemia Therapeutics Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Research Center
12.4.3. Clinic
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Renal Anemia Therapeutics Market Size and Volume Forecast by Type
12.7.1. DS-1093
12.7.2. EPO-018B
12.7.3. FG-2216
12.7.4. JTZ-951
12.7.5. MDGN-201
12.7.6. MMP-0101
12.7.7. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Renal Anemia Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Renal Anemia Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Renal Anemia Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Renal Anemia Therapeutics Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Research Center
13.4.3. Clinic
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Renal Anemia Therapeutics Market Size and Volume Forecast by Type
13.7.1. DS-1093
13.7.2. EPO-018B
13.7.3. FG-2216
13.7.4. JTZ-951
13.7.5. MDGN-201
13.7.6. MMP-0101
13.7.7. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Renal Anemia Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Renal Anemia Therapeutics Market: Market Share Analysis
14.2. Renal Anemia Therapeutics Distributors and Customers
14.3. Renal Anemia Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bayer AG
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. BIOCAD
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. CCM Duopharma Biotech Bhd.
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Chong Kun Dang Pharmaceutical Corp.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Daiichi Sankyo Company, Limited
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Dong-A Socio Group
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Dr. Reddy's Laboratories Limited
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Eli Lilly and Company
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. FibroGen, Inc.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. GlaxoSmithKline Plc
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Intas Pharmaceuticals Ltd.
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Japan Tobacco Inc.
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. JCR Pharmaceuticals Co., Ltd.
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Jiangsu Hansoh Pharmaceutical Co., Ltd.
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook